These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 29251012)

  • 21. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease.
    Rogers ZR
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):42-7. PubMed ID: 9317200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
    Charache S
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
    J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.
    Al-Jam'a AH; Al-Dabbous IA
    Saudi Med J; 2002 Mar; 23(3):277-81. PubMed ID: 11938415
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
    Ballas SK; McCarthy WF; Guo N; Brugnara C; Kling G; Bauserman RL; Waclawiw MA
    Hemoglobin; 2010; 34(5):424-9. PubMed ID: 20854115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydroxyurea in children with sickle cell disease in a resource-poor setting: Monitoring and effects of therapy. A practical perspective.
    Nnebe-Agumadu U; Adebayo I; Erigbuem I; James E; Kumode E; Nnodu O; Adekile A
    Pediatr Blood Cancer; 2021 Jun; 68(6):e28969. PubMed ID: 33788390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of hydroxyurea on hemoglobin S].
    Torres AF; Eberle SE; Sciuccati G; Bonduel M
    Medicina (B Aires); 2003; 63(2):140-2. PubMed ID: 12793083
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
    Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
    Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
    Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
    JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS).
    Voskaridou E; Christoulas D; Bilalis A; Plata E; Varvagiannis K; Stamatopoulos G; Sinopoulou K; Balassopoulou A; Loukopoulos D; Terpos E
    Blood; 2010 Mar; 115(12):2354-63. PubMed ID: 19903897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From infancy to adolescence: fifteen years of continuous treatment with hydroxyurea in sickle cell anemia.
    Hankins JS; Aygun B; Nottage K; Thornburg C; Smeltzer MP; Ware RE; Wang WC
    Medicine (Baltimore); 2014 Dec; 93(28):e215. PubMed ID: 25526439
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of Rapamycin as Inducer of Hb F in Primary Erythroid Cultures from Sickle Cell Disease and β-Thalassemia Patients.
    Pecoraro A; Troia A; Calzolari R; Scazzone C; Rigano P; Martorana A; Sacco M; Maggio A; Di Marzo R
    Hemoglobin; 2015; 39(4):225-9. PubMed ID: 26016899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydroxyurea prescription, availability and use for children with sickle cell disease in Italy: Results of a National Multicenter survey.
    Colombatti R; Palazzi G; Masera N; Notarangelo LD; Bonetti E; Samperi P; Barone A; Perrotta S; Facchini E; Miano M; Del Vecchio GC; Guerzoni ME; Corti P; Menzato F; Cesaro S; Casale M; Rigano P; Forni GL; Russo G; Sainati L;
    Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28868627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hydroxyurea in sickle cell disease--a study of clinico-pharmacological efficacy in the Indian haplotype.
    Italia K; Jain D; Gattani S; Jijina F; Nadkarni A; Sawant P; Nair S; Mohanty D; Ghosh K; Colah R
    Blood Cells Mol Dis; 2009; 42(1):25-31. PubMed ID: 18954999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hydroxyurea alters hematological, biochemical and inflammatory biomarkers in Brazilian children with SCA: Investigating associations with βS haplotype and α-thalassemia.
    Yahouédéhou SCMA; da Guarda CC; Figueiredo CVB; Santiago RP; Carvalho SP; Fiuza LM; Ndidi US; Oliveira RM; Carvalho MOS; Nascimento VML; Rocha LC; Lyra IM; Adorno EV; Goncalves MS
    PLoS One; 2019; 14(7):e0218040. PubMed ID: 31306416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective longitudinal follow-up of children with sickle cell disease treated with hydroxyurea since infancy.
    Thomas R; Dulman R; Lewis A; Notarangelo B; Yang E
    Pediatr Blood Cancer; 2019 Sep; 66(9):e27816. PubMed ID: 31157521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxyurea for the treatment of sickle cell disease.
    el-Hazmi MA; Warsy AS; al-Momen A; Harakati M
    Acta Haematol; 1992; 88(4):170-4. PubMed ID: 1292305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease.
    Steinberg MH; Voskaridou E; Kutlar A; Loukopoulos D; Koshy M; Ballas SK; Castro O; Barton F
    Am J Hematol; 2003 Feb; 72(2):121-6. PubMed ID: 12555216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alpha-thalassaemia and response to hydroxyurea in sickle cell anaemia.
    Darbari DS; Nouraie M; Taylor JG; Brugnara C; Castro O; Ballas SK
    Eur J Haematol; 2014 Apr; 92(4):341-5. PubMed ID: 24330217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea.
    Styles LA; Lubin B; Vichinsky E; Lawrence S; Hua M; Test S; Kuypers F
    Blood; 1997 Apr; 89(7):2554-9. PubMed ID: 9116302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.